# PAD Pathogenesis and Claudication

Authors: *Nedal Katib and Danielle Bajakian*

Contributors: *Eilidh Gunn*

```{r echo=FALSE}

library(embedr)

embed_audio("https://traffic.libsyn.com/audiblebleeding/PAOD_part_1_postEQ.mp3")

```

## Pathogenesis of peripheral arterial disease

**What is Peripheral Artery Occlusive Disease (PAD)?**

Peripheral Arterial Disease encompasses extremity arterial disease but generally is used to describe lower limb arterial occlusive disease. Peripheral Artery Occlusive Disease (PAD) is a more specific term and this encompasses atherosclerotic disease of the lower limb arteries.

The disease has a step-wise spectrum of presentations from asymptomatic disease to intermittent claudication and finally chronic limb threatening ischemia (CLTI) formerly known as Critical Limb Ischemia (CLI) [@aboyans2017ESCGuidelines2018]

**What is the underlying pathophysiology of PAD?**

The understanding of the underlying pathophysiology which results in occlusive arterial disease of the lower limb has evolved over the last 50 years. Atherosclerosis remains the main pathological process resulting in occlusive disease with smoking being the primary modifiable risk factor.\
Although with the rising incidence of diabetes a second population of patients with a significant PAD burden has developed.

Atherosclerosis begins with an injury to the intimal lining of the arterial wall, which, for example, can result from smoking, hypertension, hyperglycemia, or advanced age. Repeated injury leads to a chronic inflammatory process resulting in the uptake and oxidation of LDL, resulting in foam cells.[@hiltunen1998; @tsimikas2005; @witztum1994] Foam cells result when unregulated scavenger receptors promote uptake of oxidized LDL by macrophages and smooth muscle cells. These foam cells become necrotic and then create the central core of the atheroma.[@owens2019] This oxidized LDL form into intimal plaque, build up and calcification that may result in progressive vessel stenosis and subsequent occlusion, or plaque rupture with acute occlusion.

Atherosclerosis is particularly prone to developing at sites of arterial bifurcation (i.e. carotid bifurcation, femoral bifurcation) because turbulent flow and low laminar shear stress results in the down regulation of eNOS and NO production. This in turn increases V-CAM-1 and reduces inhibition of KF-kB (resulting in it's elevation.[@owens2019]

| Classification | Description                                                             |
|:----------------------:|------------------------------------------------|
|       0        | Normal artery                                                           |
|       1        | Initial atherosclerotic lesion                                          |
|       2        | Fatty streak                                                            |
|       3        | Fatty plaque/raised fatty streak                                        |
|       4        | Atheroma                                                                |
|       5        | Fibroatheroma - development of fibrotic cap, vascularization or calcium |
|       6        | Complicated lesion                                                      |

: **AHA lesion classification** - defines plaque risk for rupture/thrombosis. Extrapolated from the coronary artery disease literature.[@mcgill2000]

**What are the risk factors for atherosclerosis?**

**Modifiable:**

1.  ***Smoking***

    -   The **most significant modifiable risk factor** for developing peripheral arterial disease.

    -   Causes endothelial dysfunction by reducing nitric oxide and triggering reactive-oxygen species, platelet adhesion, and permeability of endothelial surface to fibrinogen.[@unitedstatessurgeongeneralHealthConsequencesSmoking2014; @hackam2003].

    -   Causes a prothrombotic environment by causing an increase in thromboxane A2 and decreasing prostacyclin thus overall resulting in increased prothrombotic environment for platelets.

    -   Smoking has a stronger association with Intermittent claudication than with Coronary Artery Disease! [@gordonPredispositionAtherosclerosisHead1972]

2.  ***Diabetes, Metabolic Syndrome, and Insulin Resistance***

    -   Diabetes Mellitus, after smoking, is the most significant modifiable risk factor for developing peripheral arterial disease. Both insulin resistance and hyperinsulinemia are independent risk factors for developing peripheral arterial disease.

    -   The Odds Risk for developing PAD in patients with DM ranges from 1.89 to 4.05.

    -   Factors associated with developing PAD in diabetics include female gender, chronicity/severity of DM, insulin dependence, African American race or Hispanic ethnicity.[@regensteiner2015; @selvin2006; @wattanakit2005] An increase in HbA1C by 1% correlates with a 28% increase risk of developing PAD. [@adlerUKPDS59Hyperglycemia2002]

    -   The following mechanisms may lead to PAD in diabetics

        -   Hyperglycemia reduces bioavailability of NO, which is a vasodilator, enhances endothelial function, and inhibits both platelet activation and smooth muscle migration.[@higashi2009]

        -   Hyperglycemia activates protein kinase C and thus accumulation of mitochondrial ROS and prostanoids.[@geraldes2010]

        -   Endothelial dysfunction leads to increased endothelin-1 and vasoconstriction.[@ahlborg2007]

3.  ***Hypertension***

    -   The **most common** cardiovascular risk factor worldwide.

        -   USPSTF Grade A recommendation for HTN screening confirm readings outside clinical setting or at home before initiating treatment.[@piper2014]

    -   The Incidence of PAD increases to 2.5-fold in patients with Hypertension. [@kannelUpdateEpidemiologicFeatures1985]

    -   Each 20mg increase in BP, results in a 35-63% increase risk in PAD. Recommend keeping BP \<140/90 or \<130/80 in diabetics or CKD.[@adler2000; @bavry2010; @emdin2015; @itoga2018]

4.  ***Dyslipidemia***

    -   A strong association has long been identified as a risk factor for cardiovascular disease.[@langlois2018; @diehm2004]

    -   25% cardiovascular event reduction for each 39 mg/dL (1mmol/L) reduction in LDL. [@heartprotectionstudycollaborativegroupRandomizedTrialEffects2007]

    -   JUPITER Study - Randomized rosuvastatin 20mg to placebo in healthy patients. Found significant decrease in unstable angina, myocardial infarction and stroke. However, patients had a higher incidence of physician-reported diabetes, but no difference in myopathy.[@ridker2008]

    -   Fish oil is also indicated for secondary prevention among patients with known cardiovascular disease.[@grenon2012; @kris-etherton2002; @siscovick2017]

**Non-Modifiable:**

1.  ***Age***

    -   Age is identified as a risk factor for PAD regardless of gender.

    -   Prevalence of PAD increases with age: 15% \> 70 years of age.

2.  ***Gender***

    -   The Framingham Study has found that the risk of developing PAD is doubled in men.

3.  ***Race and Ethnicity***

    -   The MESA study showed a higher prevalence of PAD (ABPI \<0.9) in African Americans compared to Whites. 7.2% versus 3.6%. [@bildMultiEthnicStudyAtherosclerosis2002]

    -   Cross Sectional analysis 6653 subjects all with ABPI assessment revealed a prevalence of PAD (\<0.9) of 4%. Non-Hispanic Whites: 3.6%, Asian: 2%, African American: 7.2% and Hispanic: 2.4%. (p\<0.01) [@allisonEffectNovelCardiovascular2006]

**What are the some of the major population-based trials looking at the natural history of atherosclerotic disease?**

1.  ***The Framingham Heart Study***: The original Cohort from the town of Framingham, n=5183 patients, followed over time for over 30 years. There have been multiple subsequent recruited populations since. The majority of information we have about risk factors related to cardiovascular health comes from this study. [@mahmoodFraminghamHeartStudy2014]

2.  ***The Rotterdam Study***: 1990, Longitudinal Study, \>7000 participants.

3.  ***CVHS***: 1989-1999 Longitudinal Study : n\>5000 Multicenter Study.

4.  ***MESA***: Cross Sectional analysis 6653 subjects all with ABPI assessment revealed a prevalence of PAD (\<0.9) of 4%. Non-Hispanic Whites: 3.6%, Asian: 2%, African American: 7.2% and Hispanic: 2.4%. (p\<0.01) [@allisonEffectNovelCardiovascular2006]

5.  ***The Edinburgh Study***: The EAS began as a cross sectional study of 1592 men and women in Edinburgh with the goal of examining the frequency of risk factors for peripheral arterial disease. The subjects were followed over 20 years. [@fowkesEdinburghArteryStudy1991]

**How does Diabetes confound the clinical picture of PAD?**

-   Increasing Incidence of Diabetes world-wide.[@boultonGlobalBurdenDiabetic2005]

    -   2.8% of the global population affected by diabetes in 2000, estimated to be 4.4% by 2030.

    -   25% of patients with diabetes develop a diabetic foot ulcer (DFU), at some stage in their lives.

    -   Diabetic foot ulcers have a very high rate of recurrence with 40% of patients developing a new ulcer within 12 months of healing a previous ulcer. [@armstrong2017]

    -   Limb Loss occurs every 20 seconds world-wide to due to Diabetes related PAD or infection.

**What's the pathophysiology of Diabetes and PAD** [@armstrong26PathophysiologyPrinciplesManagement2012]

-   Neuropathy. The loss of the basic nociceptive mechanisms in the foot among diabetics, presents as a loss of protective sensation (LOPS). Neuropathy can be divided into three types:

    -   Sensory: "stocking-glove" distribution

    -   Motor: Intrinsic muscle wasting -- resulting in deformities

    -   Autonomic: Sympathetic nervous system pathology

-   Structural deformities and gait disturbances

-   Arterial disease of large and small vessels.

    -   Large Vessel

    -   Small Vessel

    -   Both

-   Foot infection[@bandyk2018; @kayssi2019; @lepÃ¤ntalo2011]

Given the pathological effect of diabetes upon multiple structures and systems the normal progressive history of diabetes related PAD is somewhat different to smoking related PAD. Clinically due to the combined effect of peripheral neuropathy and microvascular arterial disease, foot ulceration for many patients tends to be the initial presentation. This results in a lack of a 'safety net' where presenting with progressive claudication allows for a period of detection, management and and risk factor modification before they develop tissue loss and are at risk of amputation, leading to poor outcomes and greater morbidity and mortality.

Since the publication of WIfI in 2014 a lot has changed in the way we view PAD leading up to last years new Global Vascular Guidelines on CLTI, which as a term has replaced CLI (see @sec-clti). [@millsSocietyVascularSurgery2014a; @conteGlobalVascularGuidelines2019a]

## Intermittent Claudication

**What is Intermittent Claudication and the classic patient presentation?**

The original population studies we mentioned determined the epidemiology and natural history of Intermittent Claudication based on historically validated and widely accepted questionnaires, namely the ***Rose*** [@roseDiagnosisIschaemicHeart1962] (which later was adopted by the WHO) and subsequently the ***Edinburgh questionnaire***. [@lendEdinburghClaudicationQuestionnaire1992].

All questionnaires are based on a number of key diagnostic clinical factors that define claudication, they are:

-   Onset

-   Calf Involvement

-   Reproducibility

-   Relief with Rest

-   Not Occurring at Rest

The progression of intermittent claudication was historically graded by Fontaine (1954) [@fontaineSurgicalTreatmentPeripheral1954] followed by the Rutherford Grading System (1986, Revised 1997) [@rutherfordRecommendedStandardsReports1997]

Rutherford et al. Ad Hoc Committee on Reporting Standards, SVS/North American Chapter ISCVS:

| Grade | Category |                     Clinical Description                     |
|:----------------------:|:----------------------:|:----------------------:|
|   0   |    0     | A symptomatic - no hemodynamic significant occlusive disease |
|   I   |    1     |                      Mild Claudication                       |
|   I   |    2     |                    Moderate Claudication                     |
|   I   |    3     |                     Severe Claudication                      |
|  II   |    4     |                      Ischemic Rest Pain                      |
|  III  |    5     |                      Minor Tissue Loss                       |
|  III  |    6     |                      Major Tissue Loss                       |

**Leriche Syndrome** - Is a clinical triad of: claudication (buttock, thigh, and calf), impotence, and decreased lower limb pulses, which signifies aortoiliac occlusive disease. [@frederick2010; @leriche1948; @setacci2012]

**Neurogenic Claudication** - Differentiating neurogenic claudication from vasculogenic claudication can be difficult. Vasculogenic claudication is relieved by cessation of ambulation and mostly affects a unilateral calf. Neurogenic improves with postural changes, more often bilateral and affects the thighs. [@nadeauReliabilityDifferentiatingNeurogenic2013]

**What is involved in the work up of patients with PAD/Intermittent Claudication?**

### History / Clinical Examination

***SVS Guidelines:***

"We recommend using ABPI as the first-line non-invasive test to establish a diagnosis of PAD in individuals with symptoms or signs suggestive of disease. When the ABI is borderline or normal (\>0.9) and symptoms of claudication are suggestive, we recommend an exercise ABPI."

*Grade 1 Level of Evidence A*

-   ABPI

-   Exercise ABPI

-   Ultrasound

**What is an ABPI and how is it measured?**

The AHA released guidelines on how to perform an ABPI in an attempt to standardize the method to allow for more comparable results from studies:

Divide the higher of the PT or DP pressure by the higher of the right or left Brachial SBP *(Class 1 Level of Evidence A)* [@aboyansMeasurementInterpretationAnkleBrachial2012]

Sensitivity and Specificity both \>95% (when ABPI cut off \</=0.9 -- in detecting \>/= 50% stenosis) [@yaoAnkleSystolicPressure2005; @ourielCriticalEvaluationStress1982]

|  **ABPI**  |  Interpretation  |
|:----------:|:----------------:|
|   \>1.4    | Non-compressible |
| \>0.9-1.39 |      Normal      |
|  0.5-0.9   | Mild to Mod PAD  |
|  0.0-0.5   |    Severe PAD    |

: Interpretation of ABPIs.

**What are Exercise ABPI studies?**

Constant Load Testing -- (unlike the Graded Test -- Bruce Protocol).

The physiological changes in ABPI related to exercise are due to the fact that exercise increases SBP and decreases SVR and, therefore, will affect flow through a stenosis making it more physiologically relevant during exercise. [@nicolaiReliabilityTreadmillTesting2009; @alqahtaniPredictorsChangeAnkleBrachial2018]

Walking distance has been shown to correlate with level and severity of POAD. [@strandnessHemodynamicsSurgeons1975a]

Furthermore patients with single level iliac disease may present with buttock/thigh claudication with preserved pulses. Exercise treadmill ABPI particularly useful in determining the severity of disease in these patients. [@aboyansGeneralPrognosisPatients2010]

For more on exercise testing see @sec-lab-lower-extremity

**What is the ultrasound duplex criteria for defining PAD?**

| Stenosis Category |       Peak Systolic Velocity       | Velocity Ratio | Distal Artery Spectral Waveform |
|:----------------:|:----------------:|:----------------:|:----------------:|
|      Normal       |               \<150                |     \<1.5      |      Triphasic, Normal PSV      |
|      30-49%       |              150-200               |     1.5-2      |      Triphasic, Normal PSV      |
|      50-75%       |              200-400               |      2-4       |     Monophasic, reduced PSV     |
|       \>75%       |               \>400                |      \>4       | Damped, monophasic, reduced PSV |
|     Occlusion     | No Flow -- B -mode, Terminal Thump |       NA       |               NA                |

Adapted from Stone and Hass. Vascular Laboratory: Arterial Duplex Scanning. Rutherford's Vascular Surgery and Endovascular Therapy. 2019.[@stone21VascularLaboratory2019]

**What Guidelines are there pertaining to PAD Management.**

***SVS Guidelines (2015)***

-   The SVS published the SVS practice guidelines for atherosclerotic occlusive disease of the lower extremities:**Management of asymptomatic disease and claudication**. *Conte and Pomposelli et al. JVS 2015* [@conteSocietyVascularSurgery2015]

Other Guidelines:

-   TASC 1 -2

-   European Guidelines (2017)

-   AHA Guidelines (last update 2016)

### Management

#### Medical Management {#sec-pad-medical-management}

**What is the initial management of Asymptomatic Patients with PAD?**

1.  Smoking Cessation -- Multidisciplinary comprehensive smoking cessation interventions -- repeatedly until tobacco use has stopped (Grade A -- 1)
2.  Intervention is not only not recommended, but invasive treatment is recommended against, in the absence of symptoms (Grade A -1)

**How can we medically manage asymptomatic PAD based on the SVS Guidelines?**

-   ***Anti-Platelet Therapy***

    -   The Aspirin for Asymptomatic Atherosclerosis Trial -- n=3350, aspirin versus placebo. 8 years follow up no difference in events [@fowkesAspirinPreventionCardiovascular2010] -- therefore benefit unknown
    -   Literature reviews find benefits in secondary prevention with antiplatelet monotherapy (aspirin or clopidogrel) in symptomatic PAD.[@banerjee2015] Some initial studies did demonstrate benefit from vorapaxar as well.[@rooke2013]

-   ***Statin Therapy***

    -   The Heart Protection Study [@heartprotectionstudycollaborativegroupRandomizedTrialEffects2007] - this study looked at statins in patients with PAD but not completely asymptomatic, they had other risk factors such as diabetes, IHD, cerebrovascular disease, or hypertension. Without these risk factors the benefit of Statin therapy remains unclear.

    -   However, the AHA from the Framingham Study does recommend using statins if 10-year risk based on risk calculators \>7.5% (which would be positive if PAD present).

    -   Statins are particularly useful for risk reduction of cardiovascular events in diabetics.[@cholesteroltreatmenttrialists2008; @colhoun2004; @stamler1993]

    -   Statin-associated muscle symptoms (SAMS) is the most common side effect and occurrence has been reported as high as 30% in some cohorts.[@keen2014] Other side effects are rare (1.5-5% of patients) and include DM2 new onset, neurocognitive effects, hepatotoxicity, renal toxicity and pancreatitis.[@bitzur2013; @saxon2016; @ward2019]

-   ***Exercise and Limb Function***

    -   No clear evidence that physical therapy improves the patient outcomes or quality of life.

-   ***Surveillance***

    -   No benefit from US surveillance, unclear benefit of ABPI surveillance.
    -   Patients are at higher risk of depression (almost 20%), therefore PHQ-9 and -2 are good screening tools.[@jha2019; @mcdermott2016; @ramirez2018]

**How can we medically manage Intermittent Claudication based on the SVS Guidelines?**

-   **Smoking Cessation:** Multidisciplinary comprehensive smoking cessation interventions -- repeatedly until tobacco use has stopped *(Grade A -- 1)* First line therapy is behavioral therapy + varenicline/bupropion or nicotine replacement therapy (NRT) per EAGLES trial.[@anthenelli2016; @vogeler2016]

    -   Preloading with varenicline (4 weeks) or bupropion (5-7d) prior to quitting has demonstrated higher abstinence at 12w.[@ratchford2011]

        -   Varenicline is a partial nicotine receptor agonist.[@cahill2016]

        -   Bupropion is a selective dopamine and norepinephrine uptake inhibitor.[@hughes2014]

    -   NRT is preferred if rapid onset of action is needed.[@thomsen2014] However, contraindicated in setting of recent MI, severe angina, or life threatening arrhythmias.

-   **Dyslipidaemia:** Statin Therapy Recommended -- most recent evidence on lipid therapy has suggested focusing on reducing 10-year cardiovascular event risk rather than specifically reducing lipid levels. *(Grade 1-A)*

-   **Anti-Platelet Therapy:** Aspirin therapy (75-325mg daily) is recommended to reduce cardiovascular events in patients with PAD *(Grade 1-Level A)* [@collaborationCollaborativeMetaanalysisRandomised2002; @antithrombotictrialists2009]

    -   There is evidence that Clopidogrel 75mg compared to Aspirin is better in event reduction. (CAPRIE)[@capriesteeringcommitteeRandomisedBlindedTrial1996]-- replacing Aspirin with Clopidogrel *(Grade 1-Level B)*
    -   Recent evidence from the COMPASS trial has suggested that the addition of low dose rivaroxaban (2.5mg BID) to aspirin (100mg daily) has lower MALE, composite endpoint of cardiovascular death, stroke and MI. Subgroup analysis suggested clopidogrel may be better with reduced risk of GI bleed and MACE.[@anand2018; @eikelboom2017]

-   **Diabetes Mellitus:** -- Optimization of HbA1C \< 7% *(Grade 1-Level B)*[@lajoie2019]

-   **Hypertension** -- Indicated B-Blockers for hypertension. *(Grade 1-Level B)* (there's no evidence that Beta Blockers worsens IC)

    -   Initiation of beta-blockers in the immediate preoperative period is associated with worse outcomes.[@blessberger2018; @poisestudygroup2008]

    -   ACE Inhibitors are first line in patients with heart failure, diabetes or kidney disease but should be avoided in patients with renal artery stenosis (RAS).[@barrons2016]

-   **Homocysteine** -- Recommendation against Folic Acid and Vit B12*(Grade 2 -- C)*

    -   Higher homocysteine levels are associated with PAD and risk of venous and arterial thrombosis.[@dangelo1997; @khandanpour2009; @liebman2019]

**To improve Limb Function in patients with IC:**

-   **Cilostozol** use -- IC without CHF -- 3-month Trial (Grade 2 - A)

    -   If unable to tolerate Cilostozol -- Pentoxifylline (400mg TDS) *(Grade 2 -- B)*

    -   Based on Meta-analysis 26 trials [@stevensSystematicReviewEfficacy2012]

-   **Supervised Exercise Therapy**

    -   First Line Therapy recommended SEP: minimum three times / week (30-60 min/session) for at least 12 weeks (*Grade 1 Level A*)

    -   More durable functional improvements than angioplasty alone, however no current data demonstrating impact on need for revascularization or amputation rate.[@fakhry2013; @fakhry2015; @murphy2012; @murphy2015]

    -   Meta-analysis of 32 RCTs: Placebo versus exercise: Walking Time, Walking Ability, Pain Free Walking and maximum walking distance improves. BUT no difference in ABPI, Mortality or amputation. [@laneExerciseIntermittentClaudication2017]

    -   Meta-analysis of 14 RCTs: SEP better than Non-Supervised Programs. [@hagemanSupervisedExerciseTherapy2018]

#### Open and Endovascular Management

**What is the surgical management for patients with Intermittent Claudication?**

-   With appropriate medical management and risk modification, 25% of patients will improve, 50% will remain stable and 25% will progress and requiring intervention. [@conte2015; @norgren2007]

-   **Patient Selection for Intervention:**

    -   20-30% of patients with IC who adhere to risk factor modification will have progressive symptoms that will eventually be treated with intervention.

    -   Patient selection should be based on QoL and functional impairment in an active person (loss of ability to perform occupation or that limits basic activities of daily living) rather than hemodynamic (ABPI or US) or anatomical disease progression/severity.

-   **Always remember multifactorial causes of immobility -- particularly in the elderly.**

    -   SVS recommends that invasive therapy for IC have a \>50% likelihood of sustained clinical improvement for at least 2 years.

-   **Anatomical Selection:**

    -   ***Aortoiliac Disease:***

        -   Previous TASC Classification has attempted to categorize anatomy of disease and subsequent recommendation of Endovascular versus open surgery. But as the authors of the SVS guidelines highlight, "improvements in technology and endovascular techniques have resulted in EVT replacing open surgical bypass as a primary treatment for both focal and advanced AIOD in many cases."

        -   **The majority of evidence is non randomized and meta analyses of non-randomized series.**

        -   Endovascular procedures over open surgery for focal AIOD causing IC. *(Grade 1 Evidence B)*

        -   Endovascular interventions as first line for CIA or EIZ occlusive disease-causing IC. *(Grade 1 Level B)*

        -   Hybrid recommended for Iliac disease involving CFA. *(Grade 1 Level B)*

        -   Direct Surgical reconstruction (bypass, endarterectomy) in patients with reasonable surgical risk and diffuse AIOD not amenable to endovascular approach, after one or more failed attempts at EVT, or combined occlusive and aneurysmal disease. *(Grade 1 Evidence B)*

    -   ***Infrainguinal Disease:***

        -   Reviewing historical data comparing all EVT compared with surgical bypass EVTs are less durable, especially when there's diffuse or long segments of occlusion/multilevel infrainguinal disease.

        -   **Most recommendations are based on low level evidence when comparing EVT versus Open Surgery**

        -   Focal + Not involving SFA origin = EVT *(Grade 1 Level C)*

        -   SFA 5-15cm, self-expanding stent (with or without paclitaxel) *(Grade 1 Level B)* -- NB: (This was in 2015 pre Katsanos Paper[@katsanos2018])

            -   After SFA stenting, SVS and ACC recommend at least 30d dual anti-platelet, then single anti-platelet or anti-platelet and rivaroxaban.[@hussain2018; @societyforvascularsurgerylowerextremityguidelineswritinggroup2015; @strobl2013; @tepe2012]

        -   Recommend against infrapopliteal treatment for IC *(Grade 1 Level C)*

        -   Initial Surgical Bypass *(with vein: Grade 1 Level A)*: If

            -   Diffuse FP Disease

            -   Small Caliber \<5mm

            -   Extensive Calcification in SFA

            -   Average or Low Operative Risk *(Grade 1 Level B)*
